Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SAT1 | P21673 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062486 | 0.98 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL29720506 | 0.96 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11801488 | 0.94 | CYP3A4 (0.59) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL5088049 | 0.90 | LPAR3 (0.62) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2854074 | 0.90 | LPAR3 (0.62) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL5459840 | 0.89 | CYP3A4 (0.53) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| Ammonia Solution, Strong SCHEMBL28481503 | 0.88 | CYP3A4 (0.43) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL557713 | 0.87 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11490229 | 0.87 | CYP3A4 (0.55) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL7147784 | 0.86 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071503-A | Liquid phase synthesis method of 5' -triphosphate modified oligonucleotide and application thereof | 苏州金唯智生物科技有限公司 | 2026-05-22 | — | — | CN | claimed |
| CN-120157727-A | Chemically modified adenine nucleoside triphosphate and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2025-06-17 | — | — | CN | claimed |
| CN-119241622-B | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-116814150-B | Flame-retardant waterborne polyurethane coating, preparation method thereof and microfiber leather | 浙江理工大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119264184-B | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119264184-A | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119241622-A | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119080855-A | Chemically modified cytosine nucleoside triphosphate and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2024-12-06 | — | — | CN | claimed |
| CN-118453907-A | Nucleoside chemical drug chimeric nucleic acid drug and preparation method thereof | 北京化工大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118248849-A | Sodium iron pyrophosphate material and preparation method thereof | 广东工业大学 | 2024-06-25 | — | — | CN | claimed |
| CN-103232511-A | Light-cleavable group protected deoxyuridine triphosphate derivatives and a synthesis method and applications thereof. | UNIV BEIJING | 2013-08-07 | — | — | CN | claimed |
| US-20130158249-A1 | Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives | SENA RESEARCH, INCORPORATED (US) | 2013-06-20 | — | — | US | claimed |
| JP-2004512810-A | — | — | 2004-04-30 | — | — | JP | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2001525667-A | — | — | 2001-12-11 | — | — | JP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| EP-0980424-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-02-23 | — | — | EP | claimed |
| US-5990303-A | REACTING 7-DEAZA-2-DEOXY GUANOSINE WITH A PHOSPHORYLATING AGENT TO FORM NUCLEOTIDE; USED AS GUANOSINE NUCLEOTIDE ANALOGUES FOR SEQUENCE DETERMINATION; COMPOUNDS ARE STABLE AND NONAGGREGATING | ROCHE DIAGNOSTICS GMBH (DE) | 1999-11-23 | — | — | US | claimed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158249-A1 | Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives | NUDT1, PNP, TYMP | CYP3A4 2472/4885LPAR3 3599/4885LPAR1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.